Overview of the potential use of fluvoxamine for COVID-19 and long COVID
Kenji Hashimoto
Discover Mental Health, doi:10.1007/s44192-023-00036-3
Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to public health since its emergence in late 2019. From a safety point of view, drug repurposing has received particular attention. Several clinical studies have demonstrated that the use of fluvoxamine, a selective serotonin reuptake inhibitor with potent sigma-1 receptor agonism, in the early-stage of infection might be associated with the prevention of clinical deterioration in individuals with SARS-CoV-2 infection, although several reports have shown that a low dose of fluvoxamine may be ineffective. There is increasing evidence that SARS-CoV-2 can cross the blood-brain barrier, resulting in a number of psychiatric and neurologic symptoms in COVID-19 survivors. Importantly, about half of COVID-19 survivors experience a variety of longterm sequelae, including psychiatric and neurologic symptoms, known as long COVID. In this priority review, the author presents an overview of the potential use of fluvoxamine in the treatment of COVID-19 and long COVID.
Author contributions KH did the reference search and wrote the manuscript. The author read and approved the final manuscript.
Declarations Competing interests Dr. Hashimoto is the inventor of filed patent applications on "The use of R-Ketamine in the treatment of psychiatric diseases", "(S)-norketamine and salt thereof as pharmaceutical", "R-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder", "Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases", and "R-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder" by the Chiba University. Dr. Hashimoto has also received speakers' honoraria, consultant fee, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons..
References
Aydillo, Rombauts, Stadlbauer, Aslam, Abelenda-Alonso et al., Immunological imprinting of the antibody response in COVID-19 patients, Nat Commun,
doi:10.1038/s41467-021-23977-1Bhuta, Khokher, Kesireddy, Iftikhar, Beran et al., Fluvoxamine in nonhospitalized patients with acute COVID-19 infection and the lack of efficacy in reducing rates of hospitalization, mechanical ventilation, and mortality in placebo-controlled trials: a systematic review and meta-analysis, Am J Ther,
doi:10.1097/MJT.0000000000001496Bramante, Huling, Tignanelli, Buse, Liebovitz et al., Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2201662Brimson, Prasanth, Malar, Brimson, Thitilertdecha et al., Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the sigma-1 receptor and autophagy, Expert Opin Ther Targets,
doi:10.1080/14728222.2021.1952987Calusic, Marcec, Luksa, Jurkovic, Kovac et al., Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls, Bri J Clin Pharmacol,
doi:10.1111/bcp.15126Cheema, Jafar, Elrashedy, Shahid, Awan et al., Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients, J Infect,
doi:10.1016/j.jinf.2022.10.012Deng, Rayner, Ramaraju, Abbas, Carcia et al., Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis, Clin Microbiol Infect,
doi:10.1016/j.cmi.2023.01.010Diaz, Baweja, Protective effect of fluvoxamine for COVID-19 in obsessive-compulsive disorder: a real-world case-control study, Prim Care Comp CNS Disord,
doi:10.4088/PCC.22br03337Dong, Zhang, Yao, Ren, Yang et al., Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-alpha, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration, Pharmacol Biochem Behav,
doi:10.1016/j.pbb.2016.02.005Douaud, Lee, Alfaro-Almagro, Arthofer, Wang et al., SARS-CoV-2 is associated with changes in brain structure in UK Biobank, Nature,
doi:10.1038/s41586-022-04569-5Erickson, Rhea, Knopp, Banks, Interactions of SARS-CoV-2 with the blood-brain barrier, Int J Mol Sci,
doi:10.3390/ijms22052681Fenton, Lee, Antidepressants with anti-inflammatory properties may be useful in long COVID depression, Drugs Ther Perspect,
doi:10.1007/s40267-022-00975-xFico, Isayeva, Prisco, Oliva, Solè et al., Psychotropic drug repurposing for COVID-19: a systematic review and meta-analysis, Eur Neuropsychopharmacol,
doi:10.1016/j.euroneuro.2022.10.004Friesland, Mingorance, Chung, Chisari, Gastaminza, Sigma-1 receptor regulates early steps of viral RNA replication at the inset of hepatitis C virus infection, J Virol,
doi:10.1128/JVI.03557-12Gordon, Hiatt, Bouhaddou, Rezelj, Ulferts et al., Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms, Science,
doi:10.1126/science.abe9403Gordon, Jang, Bouhaddou, Xu, Obernier et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature,
doi:10.1038/s41586-020-2286-9Gorman, Kane, Mcauley, Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequalae, and management, Lancet,
doi:10.1016/S0140-6736(22)01439-8Groff, Sun, Ssentongo, Ba, Parsons et al., Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.28568Gulbins, Palmada, Reichel, Lüth, Böhmer et al., Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs, Nat Med,
doi:10.1038/nm.3214Gulbins, Schumacher, Becker, Wilker, Soddemann et al., Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide, Mol Psychiatry,
doi:10.1038/s41380-018-0090-9Guo, Harari, Chernecki, Thorlund, Forrest, Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials, Am J Trop Med Hyg,
doi:10.4269/ajtmh.21-1310Hanner, Moebius, Flandorfer, Knaus, Striessnig et al., Purification, molecular cloning, and expression of the mammalian sigma 1 -binding site, Proc Natl Acad Sci,
doi:10.1073/pnas.93.15.8072Hanson, Abbafati, Aerts, Al-Aly, Ashbaugh et al., Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021, JAMA,
doi:10.1001/jama.2022.18931Hashimoto, Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication, J Pharmacol Sci,
doi:10.1016/j.jphs.2014.11.010Hashimoto, Fujita, Iyo, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors, Neuropsychopharmacology,
doi:10.1038/sj.npp.1301047Hashimoto, Goromaru, High-affinity [ 3 H]6-nitroquipazine binding to the 5-hydroxytryptamine transport system in rat lung, Biochem Pharmacol,
doi:10.1016/0006-2952(91)90169-6Hashimoto, Goromaru, High-affinity binding of [ 3 H]6-nitroquipazine to 5-hydroxytryptamine transporter in human platelets, Eur J Pharmacol,
doi:10.1016/0014-2999(90)90356-bHashimoto, Inflammatory biomarkers as differential predictors of antidepressant response, Int J Mol Sci,
doi:10.3390/ijms16047796Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01231-xHashimoto, Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression, Prog Neurobiol,
doi:10.1016/j.pneurobio.2012.09.001Hashimoto, Suzuki, Hashimoto, Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki, Mol Psychiatry,
doi:10.1038/s41380-022-01546-2Hayashi, Su, Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca 2+ signaling and cell survival, Cell,
doi:10.1016/j.cell.2007.08.036Hindmarch, Hashimoto, Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered, Hum Psychopharmacol,
doi:10.1002/hup.1106Hoertel, Sánchez-Rico, Gulbins, Kornhuber, Carpinteiro et al., Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study, Clin Pharmacol Ther,
doi:10.1002/cpt.2317Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4Ishikawa, Ishiwata, Ishii, Kimura, Sakata et al., High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [ 11 C]SA4503, Biol Psychiatry,
doi:10.1016/j.biopsych.2007.04.001Ishima, Fujita, Hashimoto, Interactions of new antidepressants with sigma-1 receptor chaperons and their potentiation of neurite outgrowth in PC12 cells, Eur J Pharmacol,
doi:10.1016/j.ejphar.2014.01.064Ishima, Fujita, Kohno, Kunitachi, Hotio et al., Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline, Open Clin Chem J,
doi:10.2174/1874241600902010007Karlstad, Hovi, Husby, Härkänen, Selmer et al., SARS-CoV-2 vaccination and mycarditis in a Nordic cohort study of 23 million residents, JAMA Cardiol,
doi:10.1001/jamacardio.2022.0583Kim, Huh, Park, Peck, Jung, Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection, JAMA,
doi:10.1001/jama.2022.12992Kirenga, Mugenyi, Sánchez-Rico, Kyobe, Muttamba et al., Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study, Mol Psychiatry,
doi:10.1038/s41380-023-02004-3Kondratiuk, Pillay, Kon, Lalvani, A conceptual framework to accelerate the clinical impact of evolving research into long COVID, Lancet Infect Dis,
doi:10.1016/S1473-3099(21)00136-5Kornhuber, Muehlbacher, Trapp, Pechmann, Friedl et al., Identification of novel functional inhibitors of acid sphingomyelinase, PLoS ONE,
doi:10.1371/journal.pone.0023852Kornhuber, Tripal, Reichel, Mühle, Rhein et al., Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications, Cell Physiol Biochem,
doi:10.1159/000315101Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for outpatients management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2022.6269Lenze, Fluvoxamine for early treatment of Covid-19 (Stop Covid 2
Lenze, Mattar, Zorumski, Zorumski, Stevens et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial, JAMA,
doi:10.1001/jama.2020.22760Li, Wang, Wu, Gulbins, Grassmé et al., Acid sphingomyelinase-ceramide system in bacterial infections, Cell Physiol Biochem,
doi:10.33594/000000021Lu, Chao, Chang, Lan, Lai, Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: a systematic review and meta-analysis, J Infect Public Health,
doi:10.1016/j.jiph.2022.10.010Mahdi, Hermán, Réthelyi, Bálint, Potential role of the antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19, Int J Mol Sci,
doi:10.3390/ijms23073812Marcec, Dodig, Likic, A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference, J Infect,
doi:10.1016/j.jinf.2022.11.011Maurer-Spurej, Pittendreigh, Solomons, The influence of selective serotonin reuptake inhibitors on human platelet serotonin, Thromb Haemost,
doi:10.1160/TH03-05-0330Mccarthy, Naggie, Boulware, Lindsell, Stewart et al., Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2022.24100Mercado, Killic, Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels, Mol Interv,
doi:10.1124/mi.10.4.6Mills, Reis, Wilson, Thorlund, Forrest et al., Early treatment with fluvoxamine among patients with COVID-19: a costconsequence model, Am J Trop Med Hyg,
doi:10.4269/ajtmh.22-0106Narita, Hashimoto, Tomitaka, Minabe, Interaction of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain, Eur J Pharmacol,
doi:10.1016/0014-2999(96)00254-3Nishimura, Ishima, Iyo, Hashimoto, Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP 3 receptors and cellular signaling pathways, PLoS ONE,
doi:10.1371/journal.pone.0002558Ohgi, Futamura, Kikuchi, Hashimoto, Effects of antidepressants on alterations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration, Pharmacol Biochem Behav,
doi:10.1016/j.pbb.2012.12.003Oldfield, Hibberd, Bridle, How does severe acute respiratory syndrome-coronavirus-2 affect the brain and its implications for the vaccines currently in use, Vaccines,
doi:10.3390/vaccines10010001Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.33090Oster, Shay, Su, Gee, Creech et al., Myocarditis cases reported after mRN-based COVID-19 vaccination in the US from December 2020 to August 2021, JAMA,
doi:10.1001/jama.2021.24110Owens, Knight, Nemeroff, Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine, Biol Psychiatry,
doi:10.1016/s0006-3223(01)01145-3Pavord, Hunt, Horner, Bewley, Karpusheff et al., Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance, BMJ,
doi:10.1136/bmj.n2195Petrovszki, Walter, Vigh, Kocsis, Valkai et al., Penetration of the SARS-CoV-2 spike protein across the blood-brain barrier, as revealed by a combination of a human cell culture model system and optical biosensing, Biomedicines,
doi:10.3390/biomedicines10010188Pineda, Singh, Pineda, Umanzor, Baires et al., Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study, Front Pharmacol,
doi:10.3389/fphar.2022.1054644Puelles, Lütgehetmann, Lindenmeyer, Sperhake, Wong et al., Multiorgan and renal tropism of SARS-CoV-2, N Engl J Med,
doi:10.1056/NEJMc2011400Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized, platform clinical trial, Lancet Glob Health,
doi:10.1016/S2214-109X(21)00448-4Rhea, Logsdon, Hansen, Williams, Reed et al., The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice, Nat Neurosci,
doi:10.1038/s41593-020-00771-8Rosen, Seki, Fernández-Castañeda, Beiter, Eccles et al., Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med,
doi:10.1126/scitranslmed.aau5266Seftel, Boulware, Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab050Seo, Kim, Bae, Park, Chung et al., Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial, Infect Chemother,
doi:10.3947/ic.2021.0142Sidky, Sahner, Girvin, Hotaling, Michael et al., Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19, medRxiv,
doi:10.1101/2022.11.09.22282142Sollmann, Beer, Kirchhoff, SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases, Signal Transduct Target Ther,
doi:10.1038/s41392-022-01072-1Solomon, Normandin, Bhattacharyya, Mukerji, Keller et al., Neurological features of Covid-19, N Engl J Med,
doi:10.1056/NEJMc2019373Song, Zhang, Israelow, Lu-Culligan, Prado et al., Neuroinvasion of SARS-CoV-2 in human and mouse brain, J Exp Med,
doi:10.1084/jem.20202135Soriano, Murthy, Marshall, Relan, Diaz, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus, Lancet Infect Dis,
doi:10.1016/S1473-3099(21)00703-9Stefanou, Palaiodimou, De Sousa, Theodorou, Bakola et al., Acute arterial ischemic stroke following COVID-19 vaccination: a systematic review and meta-analysis, Neurology,
doi:10.1212/WNL.0000000000200996Stein, Ramelli, Grazioli, Chung, Singh et al., SARS-CoV-2 infection and persistence in the human body and brain at autopsy, Nature,
doi:10.1038/s41586-022-05542-ySukhatme, Reiersen, Vayttaden, Sykhatme, Fluvoxamine: a review of its mechanisms of actions and its role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688Takano, Suhara, Sudo, Inoue, Hashimoto et al., Comparative evaluation of two serotonin transporter ligands in the human brain: [ 11 C](+)McN5652 and [ 11 C]cyanoimipramine, Eur J Nucl Med,
doi:10.1007/s00259-002-0884-4Trkulja, There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: a comment on two recent meta-analyses advocating its use, J Infect,
doi:10.1016/j.jinf.2022.11.016Törnquist, Asghar, Srinivasan, Korhonen, Lindholm, Sphingolipids as modulators of SARS-CoV-2 infection, Front Cell Dev Biol,
doi:10.3389/fcell.2021.689854Wang, Wang, Liu, Qiao, Baldwin et al., Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis, Brain Behav Immun,
doi:10.1016/j.bbi.2019.02.021Wu, Xu, Chen, Duan, Hashimoto et al., Nervous system involvement after infection with COVID-19 and other coronaviruses, Brain Behav Immun,
doi:10.1016/j.bbi.2020.03.031Zeng, Zhao, Li, Lu, Liu, A systematic review and meta-analysis of long-term physical and mental sequelae of COVID-19 pandemic: call for research priority and action, Mol Psychiatry,
doi:10.1038/s41380-022-01614-7Zhang, Xie, Hashimoto, Current status of potential therapeutic candidates for the COVID-19 crisis, Brain Behav Immun,
doi:10.1016/j.bbi.2020.04.046Zhang, Zhou, Bao, Liu, Zhu et al., SAES-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration, Signal Transduct Target,
doi:10.1038/s41392-021-00719-9{ 'indexed': {'date-parts': [[2023, 3, 22]], 'date-time': '2023-03-22T05:00:01Z', 'timestamp': 1679461201237},
'reference-count': 107,
'publisher': 'Springer Science and Business Media LLC',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2023, 3, 21]],
'date-time': '2023-03-21T00:00:00Z',
'timestamp': 1679356800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'},
{ 'start': { 'date-parts': [[2023, 3, 21]],
'date-time': '2023-03-21T00:00:00Z',
'timestamp': 1679356800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'}],
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'abstract': '<jats:title>Abstract</jats:title><jats:p>Coronavirus disease 2019 (COVID-19) has presented a '
'serious worldwide threat to public health since its emergence in late 2019. From a safety '
'point of view, drug repurposing has received particular attention. Several clinical studies '
'have demonstrated that the use of fluvoxamine, a selective serotonin reuptake inhibitor with '
'potent sigma-1 receptor agonism, in the early-stage of infection might be associated with the '
'prevention of clinical deterioration in individuals with SARS-CoV-2 infection, although '
'several reports have shown that a low dose of fluvoxamine may be ineffective. There is '
'increasing evidence that SARS-CoV-2 can cross the blood–brain barrier, resulting in a number '
'of psychiatric and neurologic symptoms in COVID-19 survivors. Importantly, about half of '
'COVID-19 survivors experience a variety of long-term sequelae, including psychiatric and '
'neurologic symptoms, known as long COVID. In this priority review, the author presents an '
'overview of the potential use of fluvoxamine in the treatment of COVID-19 and long '
'COVID.</jats:p>',
'DOI': '10.1007/s44192-023-00036-3',
'type': 'journal-article',
'created': {'date-parts': [[2023, 3, 21]], 'date-time': '2023-03-21T14:05:01Z', 'timestamp': 1679407501000},
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Overview of the potential use of fluvoxamine for COVID-19 and long COVID',
'prefix': '10.1007',
'volume': '3',
'author': [{'given': 'Kenji', 'family': 'Hashimoto', 'sequence': 'first', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2023, 3, 21]]},
'reference': [ { 'issue': '4',
'key': '36_CR1',
'doi-asserted-by': 'publisher',
'first-page': '331',
'DOI': '10.1001/jama.2021.24110',
'volume': '327',
'author': 'ME Oster',
'year': '2022',
'unstructured': 'Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. '
'Myocarditis cases reported after mRN-based COVID-19 vaccination in the '
'US from December 2020 to August 2021. JAMA. 2022;327(4):331–40. '
'https://doi.org/10.1001/jama.2021.24110.',
'journal-title': 'JAMA'},
{ 'issue': '6',
'key': '36_CR2',
'doi-asserted-by': 'publisher',
'first-page': '600',
'DOI': '10.1001/jamacardio.2022.0583',
'volume': '7',
'author': 'Ø Karlstad',
'year': '2022',
'unstructured': 'Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. '
'SARS-CoV-2 vaccination and mycarditis in a Nordic cohort study of 23 '
'million residents. JAMA Cardiol. 2022;7(6):600–12. '
'https://doi.org/10.1001/jamacardio.2022.0583.',
'journal-title': 'JAMA Cardiol'},
{ 'issue': '10306',
'key': '36_CR3',
'doi-asserted-by': 'publisher',
'first-page': '1147',
'DOI': '10.1016/S0140-6736(21)01608-1',
'volume': '398',
'author': 'RJ Perry',
'year': '2021',
'unstructured': 'Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, '
'et al. Cerebral venous thrombosis after vaccination against. Lancet. '
'2021;398(10306):1147–56. https://doi.org/10.1016/S0140-6736(21)01608-1.',
'journal-title': 'Lancet'},
{ 'key': '36_CR4',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.n2195',
'volume': '375',
'author': 'S Pavord',
'year': '2021',
'unstructured': 'Pavord S, Hunt BJ, Horner D, Bewley S, Karpusheff J, Guideline '
'Committee. Vaccine induced immune thrombocytopenia and thrombosis: '
'summary of NICE guidance. BMJ. 2021;375: n2195. '
'https://doi.org/10.1136/bmj.n2195.',
'journal-title': 'BMJ'},
{ 'issue': '9',
'key': '36_CR5',
'doi-asserted-by': 'publisher',
'first-page': '887',
'DOI': '10.1001/jama.2022.12992',
'volume': '328',
'author': 'YE Kim',
'year': '2022',
'unstructured': 'Kim YE, Huh K, Park YJ, Peck KR, Jung J. Association between vaccination '
'and acute myocardial infarction and ischemic stroke after COVID-19 '
'infection. JAMA. 2022;328(9):887–9. '
'https://doi.org/10.1001/jama.2022.12992.',
'journal-title': 'JAMA'},
{ 'key': '36_CR6',
'doi-asserted-by': 'publisher',
'author': 'MI Stefanou',
'year': '2022',
'unstructured': 'Stefanou MI, Palaiodimou L, Aguiar de Sousa D, Theodorou A, Bakola E, '
'Katsaros DE, et al. Acute arterial ischemic stroke following COVID-19 '
'vaccination: a systematic review and meta-analysis. Neurology. 2022. '
'https://doi.org/10.1212/WNL.0000000000200996.',
'journal-title': 'Neurology',
'DOI': '10.1212/WNL.0000000000200996'},
{ 'issue': '7944',
'key': '36_CR7',
'doi-asserted-by': 'publisher',
'first-page': '428',
'DOI': '10.1038/d41586-023-00086-1',
'volume': '613',
'author': 'R Brazil',
'year': '2023',
'unstructured': 'Brazil R. How your first brush with COVID warps your immunity. Nature. '
'2023;613(7944):428–30. https://doi.org/10.1038/d41586-023-00086-1.',
'journal-title': 'Nature'},
{ 'issue': '1',
'key': '36_CR8',
'doi-asserted-by': 'publisher',
'first-page': '3781',
'DOI': '10.1038/s41467-021-23977-1',
'volume': '12',
'author': 'T Aydillo',
'year': '2021',
'unstructured': 'Aydillo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, '
'Escalera A, et al. Immunological imprinting of the antibody response in '
'COVID-19 patients. Nat Commun. 2021;12(1):3781. '
'https://doi.org/10.1038/s41467-021-23977-1.',
'journal-title': 'Nat Commun'},
{ 'issue': '1',
'key': '36_CR9',
'doi-asserted-by': 'publisher',
'first-page': '249',
'DOI': '10.1007/s00406-020-01231-x',
'volume': '271',
'author': 'K Hashimoto',
'year': '2021',
'unstructured': 'Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: '
'targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. '
'2021;271(1):249–58. https://doi.org/10.1007/s00406-020-01231-x.',
'journal-title': 'Eur Arch Psychiatry Clin Neurosci'},
{ 'issue': '1',
'key': '36_CR10',
'doi-asserted-by': 'publisher',
'first-page': '161',
'DOI': '10.1007/s00406-021-01326-z',
'volume': '272',
'author': 'Y Hashimoto',
'year': '2022',
'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for '
'COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):161–3. '
'https://doi.org/10.1007/s00406-021-01326-z.',
'journal-title': 'Eur Arch Psychiatry Clin Neurosci'},
{ 'issue': '4',
'key': '36_CR11',
'doi-asserted-by': 'publisher',
'first-page': '1898',
'DOI': '10.1038/s41380-021-01432-3',
'volume': '27',
'author': 'Y Hashimoto',
'year': '2022',
'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Mechanisms of action of fluvoxamine '
'for COVID-19: a historical review. Mol Psychiatry. 2022;27(4):1898–907. '
'https://doi.org/10.1038/s41380-021-01432-3.',
'journal-title': 'Mol Psychiatry'},
{ 'key': '36_CR12',
'doi-asserted-by': 'publisher',
'first-page': '59',
'DOI': '10.1016/j.bbi.2020.04.046',
'volume': '87',
'author': 'J Zhang',
'year': '2020',
'unstructured': 'Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic '
'candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59–73. '
'https://doi.org/10.1016/j.bbi.2020.04.046.',
'journal-title': 'Brain Behav Immun'},
{ 'key': '36_CR13',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.pharmthera.2021.107930',
'volume': '228',
'author': 'YL Ng',
'year': '2021',
'unstructured': 'Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, '
'challenges and promising candidates. Pharmacol Ther. 2021;228: 107930. '
'https://doi.org/10.1016/j.pharmthera.2021.107930.',
'journal-title': 'Pharmacol Ther'},
{ 'issue': '7',
'key': '36_CR14',
'doi-asserted-by': 'publisher',
'first-page': 'e63',
'DOI': '10.1016/S2213-2600(21)00270-8',
'volume': '9',
'author': 'P Venkatesan',
'year': '2021',
'unstructured': 'Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir '
'Med. 2021;9(7):e63. https://doi.org/10.1016/S2213-2600(21)00270-8.',
'journal-title': 'Lancet Respir Med'},
{ 'key': '36_CR15',
'doi-asserted-by': 'publisher',
'first-page': '30',
'DOI': '10.1016/j.euroneuro.2022.10.004',
'volume': '66',
'author': 'G Fico',
'year': '2023',
'unstructured': 'Fico G, Isayeva U, De Prisco M, Oliva V, Solè B, Montejo L, et al. '
'Psychotropic drug repurposing for COVID-19: a systematic review and '
'meta-analysis. Eur Neuropsychopharmacol. 2023;66:30–44. '
'https://doi.org/10.1016/j.euroneuro.2022.10.004.',
'journal-title': 'Eur Neuropsychopharmacol'},
{ 'issue': '22',
'key': '36_CR16',
'doi-asserted-by': 'publisher',
'first-page': '2292',
'DOI': '10.1001/jama.2020.22760',
'volume': '324',
'author': 'E Lenze',
'year': '2020',
'unstructured': 'Lenze E, Mattar C, Zorumski CF, Zorumski CF, Stevens A, Schweiger J, et '
'al. Fluvoxamine vs placebo and clinical deterioration in outpatients '
'with symptomatic COVID-19. A randomized clinical trial. JAMA. '
'2020;324(22):2292–300. https://doi.org/10.1001/jama.2020.22760.',
'journal-title': 'JAMA'},
{ 'issue': '6',
'key': '36_CR17',
'doi-asserted-by': 'publisher',
'first-page': '756',
'DOI': '10.1016/S1473-3099(21)00136-5',
'volume': '21',
'author': 'AL Kondratiuk',
'year': '2021',
'unstructured': 'Kondratiuk AL, Pillay TD, Kon OM, Lalvani A. A conceptual framework to '
'accelerate the clinical impact of evolving research into long COVID. '
'Lancet Infect Dis. 2021;21(6):756–7. '
'https://doi.org/10.1016/S1473-3099(21)00136-5.',
'journal-title': 'Lancet Infect Dis'},
{ 'issue': '16',
'key': '36_CR18',
'doi-asserted-by': 'publisher',
'first-page': '1604',
'DOI': '10.1001/jama.2022.18931',
'volume': '328',
'author': 'S Wulf Hanson',
'year': '2022',
'unstructured': 'Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et '
'al. Estimated global proportions of individuals with persistent fatigue, '
'cognitive, and respiratory symptom clusters following symptomatic '
'COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15. '
'https://doi.org/10.1001/jama.2022.18931.',
'journal-title': 'JAMA'},
{ 'issue': '10358',
'key': '36_CR19',
'doi-asserted-by': 'publisher',
'first-page': '1157',
'DOI': '10.1016/S0140-6736(22)01439-8',
'volume': '400',
'author': 'EA Gorman',
'year': '2022',
'unstructured': 'Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in '
'adults: diagnosis, outcomes, long-term sequalae, and management. Lancet. '
'2022;400(10358):1157–70. https://doi.org/10.1016/S0140-6736(22)01439-8.',
'journal-title': 'Lancet'},
{ 'issue': '4',
'key': '36_CR20',
'doi-asserted-by': 'publisher',
'first-page': 'e102',
'DOI': '10.1016/S1473-3099(21)00703-9',
'volume': '22',
'author': 'JB Soriano',
'year': '2022',
'unstructured': 'Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case '
'Definition Working Group on Post-COVID-19 Condition. A clinical case '
'definition of post-COVID-19 condition by a Delphi consensus. Lancet '
'Infect Dis. 2022;22(4):e102–7. '
'https://doi.org/10.1016/S1473-3099(21)00703-9.',
'journal-title': 'Lancet Infect Dis'},
{ 'issue': '1',
'key': '36_CR21',
'doi-asserted-by': 'publisher',
'first-page': '423',
'DOI': '10.1038/s41380-022-01614-7',
'volume': '28',
'author': 'N Zeng',
'year': '2023',
'unstructured': 'Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review '
'and meta-analysis of long-term physical and mental sequelae of COVID-19 '
'pandemic: call for research priority and action. Mol Psychiatry. '
'2023;28(1):423–33. https://doi.org/10.1038/s41380-022-01614-7.',
'journal-title': 'Mol Psychiatry'},
{ 'issue': '36',
'key': '36_CR22',
'doi-asserted-by': 'publisher',
'DOI': '10.1073/pnas.2213524119',
'volume': '119',
'author': 'L Shaffer',
'year': '2022',
'unstructured': 'Shaffer L. Lots of long COVID treatment leads, but few are proven. Proc '
'Natl Acad Sci USA. 2022;119(36): e2213524119. '
'https://doi.org/10.1073/pnas.2213524119.',
'journal-title': 'Proc Natl Acad Sci USA'},
{ 'key': '36_CR23',
'doi-asserted-by': 'publisher',
'first-page': '365',
'DOI': '10.1007/978-3-642-38664-0_15',
'volume': '218',
'author': 'S Adnot',
'year': '2013',
'unstructured': 'Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin '
'transporter and serotonin receptors. Handb Exp Pharmacol. '
'2013;218:365–80. https://doi.org/10.1007/978-3-642-38664-0_15.',
'journal-title': 'Handb Exp Pharmacol'},
{ 'issue': '11',
'key': '36_CR24',
'doi-asserted-by': 'publisher',
'first-page': '1679',
'DOI': '10.1016/0006-2952(91)90169-6',
'volume': '41',
'author': 'K Hashimoto',
'year': '1991',
'unstructured': 'Hashimoto K, Goromaru T. High-affinity [3H]6-nitroquipazine binding to '
'the 5-hydroxytryptamine transport system in rat lung. Biochem Pharmacol. '
'1991;41(11):1679–82. https://doi.org/10.1016/0006-2952(91)90169-6.',
'journal-title': 'Biochem Pharmacol'},
{ 'issue': '10',
'key': '36_CR25',
'doi-asserted-by': 'publisher',
'first-page': '1289',
'DOI': '10.1007/s00259-002-0884-4',
'volume': '29',
'author': 'A Takano',
'year': '2002',
'unstructured': 'Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, Zhang MR, et al. '
'Comparative evaluation of two serotonin transporter ligands in the human '
'brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med. '
'2002;29(10):1289–97. https://doi.org/10.1007/s00259-002-0884-4.',
'journal-title': 'Eur J Nucl Med'},
{ 'issue': '3',
'key': '36_CR26',
'doi-asserted-by': 'publisher',
'first-page': '295',
'DOI': '10.1016/0014-2999(90)90356-b',
'volume': '187',
'author': 'K Hashimoto',
'year': '1990',
'unstructured': 'Hashimoto K, Goromaru T. High-affinity binding of [3H]6-nitroquipazine '
'to 5-hydroxytryptamine transporter in human platelets. Eur J Pharmacol. '
'1990;187(3):295–302. https://doi.org/10.1016/0014-2999(90)90356-b.',
'journal-title': 'Eur J Pharmacol'},
{ 'issue': '1',
'key': '36_CR27',
'doi-asserted-by': 'publisher',
'first-page': '119',
'DOI': '10.1160/TH03-05-0330',
'volume': '91',
'author': 'E Maurer-Spurej',
'year': '2004',
'unstructured': 'Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective '
'serotonin reuptake inhibitors on human platelet serotonin. Thromb '
'Haemost. 2004;91(1):119–28. https://doi.org/10.1160/TH03-05-0330.',
'journal-title': 'Thromb Haemost'},
{ 'issue': '4',
'key': '36_CR28',
'doi-asserted-by': 'publisher',
'first-page': '231',
'DOI': '10.1124/mi.10.4.6',
'volume': '10',
'author': 'CP Mercado',
'year': '2010',
'unstructured': 'Mercado CP, Killic F. Molecular mechanisms of SERT in platelets: '
'regulation of plasma serotonin levels. Mol Interv. 2010;10(4):231–41. '
'https://doi.org/10.1124/mi.10.4.6.',
'journal-title': 'Mol Interv'},
{ 'issue': '5',
'key': '36_CR29',
'doi-asserted-by': 'publisher',
'first-page': '345',
'DOI': '10.1016/s0006-3223(01)01145-3',
'volume': '50',
'author': 'MJ Owens',
'year': '2001',
'unstructured': 'Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human '
'monoamine transporter binding profile of escitalopram and R-fluoxetine. '
'Biol Psychiatry. 2001;50(5):345–50. '
'https://doi.org/10.1016/s0006-3223(01)01145-3.',
'journal-title': 'Biol Psychiatry'},
{ 'issue': '4',
'key': '36_CR30',
'doi-asserted-by': 'publisher',
'first-page': '853',
'DOI': '10.1016/j.pbb.2012.12.003',
'volume': '103',
'author': 'Y Ohgi',
'year': '2013',
'unstructured': 'Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants '
'on alterations in serum cytokines and depressive-like behavior in mice '
'after lipopolysaccharide administration. Pharmacol Biochem Behav. '
'2013;103(4):853–9. https://doi.org/10.1016/j.pbb.2012.12.003.',
'journal-title': 'Pharmacol Biochem Behav'},
{ 'key': '36_CR31',
'doi-asserted-by': 'publisher',
'first-page': '7',
'DOI': '10.1016/j.pbb.2016.02.005',
'volume': '144',
'author': 'C Dong',
'year': '2016',
'unstructured': 'Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, et al. Effects of '
'escitalopram, R-citalopram, and reboxetine on serum levels of tumor '
'necrosis factor-alpha, interleukin-10, and depression-like behavior in '
'mice after lipopolysaccharide administration. Pharmacol Biochem Behav. '
'2016;144:7–12. https://doi.org/10.1016/j.pbb.2016.02.005.',
'journal-title': 'Pharmacol Biochem Behav'},
{ 'issue': '4',
'key': '36_CR32',
'doi-asserted-by': 'publisher',
'first-page': '7796',
'DOI': '10.3390/ijms16047796',
'volume': '16',
'author': 'K Hashimoto',
'year': '2015',
'unstructured': 'Hashimoto K. Inflammatory biomarkers as differential predictors of '
'antidepressant response. Int J Mol Sci. 2015;16(4):7796–801. '
'https://doi.org/10.3390/ijms16047796.',
'journal-title': 'Int J Mol Sci'},
{ 'key': '36_CR33',
'doi-asserted-by': 'publisher',
'first-page': '24',
'DOI': '10.1016/j.bbi.2019.02.021',
'volume': '79',
'author': 'L Wang',
'year': '2019',
'unstructured': 'Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on '
'peripheral inflammatory markers in patients with major depressive '
'disorder: a systematic review and meta-analysis. Brain Behav Immun. '
'2019;79:24–38. https://doi.org/10.1016/j.bbi.2019.02.021.',
'journal-title': 'Brain Behav Immun'},
{ 'issue': '9',
'key': '36_CR34',
'doi-asserted-by': 'publisher',
'first-page': '5199',
'DOI': '10.1038/s41380-021-01021-4',
'volume': '26',
'author': 'N Hoertel',
'year': '2021',
'unstructured': 'Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et '
'al. Association between antidepressant use and reduced risk of '
'intubation or death in hospitalized patients with COVID-19: results from '
'an observational study. Mol Psychiatry. 2021;26(9):5199–212. '
'https://doi.org/10.1038/s41380-021-01021-4.',
'journal-title': 'Mol Psychiatry'},
{ 'issue': '15',
'key': '36_CR35',
'doi-asserted-by': 'publisher',
'first-page': '8072',
'DOI': '10.1073/pnas.93.15.8072',
'volume': '93',
'author': 'M Hanner',
'year': '1996',
'unstructured': 'Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, '
'et al. Purification, molecular cloning, and expression of the mammalian '
'sigma1-binding site. Proc Natl Acad Sci USA. 1996;93(15):8072–7. '
'https://doi.org/10.1073/pnas.93.15.8072.',
'journal-title': 'Proc Natl Acad Sci USA'},
{ 'issue': '3',
'key': '36_CR36',
'doi-asserted-by': 'publisher',
'first-page': '596',
'DOI': '10.1016/j.cell.2007.08.036',
'volume': '131',
'author': 'T Hayashi',
'year': '2007',
'unstructured': 'Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion '
'interface regulate Ca2+ signaling and cell survival. Cell. '
'2007;131(3):596–610. https://doi.org/10.1016/j.cell.2007.08.036.',
'journal-title': 'Cell'},
{ 'issue': '1',
'key': '36_CR37',
'doi-asserted-by': 'publisher',
'first-page': '117',
'DOI': '10.1016/0014-2999(96)00254-3',
'volume': '307',
'author': 'N Narita',
'year': '1996',
'unstructured': 'Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interaction of selective '
'serotonin reuptake inhibitors with subtypes of sigma receptors in rat '
'brain. Eur J Pharmacol. 1996;307(1):117–9. '
'https://doi.org/10.1016/0014-2999(96)00254-3.',
'journal-title': 'Eur J Pharmacol'},
{ 'issue': '3',
'key': '36_CR38',
'doi-asserted-by': 'publisher',
'first-page': '514',
'DOI': '10.1038/sj.npp.1301047',
'volume': '32',
'author': 'K Hashimoto',
'year': '2007',
'unstructured': 'Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits '
'in mice are improved by subsequent subchronic administration of '
'fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. '
'2007;32(3):514–21. https://doi.org/10.1038/sj.npp.1301047.',
'journal-title': 'Neuropsychopharmacology'},
{ 'key': '36_CR39',
'doi-asserted-by': 'publisher',
'first-page': '7',
'DOI': '10.2174/1874241600902010007',
'volume': '2',
'author': 'T Ishima',
'year': '2009',
'unstructured': 'Ishima T, Fujita Y, Kohno M, Kunitachi S, Hotio M, Takatsu Y, et al. '
'Improvement of phencyclidine-induced cognitive deficits in mice by '
'subsequent subchronic administration of fluvoxamine, but not sertraline. '
'Open Clin Chem J. 2009;2:7–11. '
'https://doi.org/10.2174/1874241600902010007.',
'journal-title': 'Open Clin Chem J'},
{ 'issue': '7',
'key': '36_CR40',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0002558',
'volume': '3',
'author': 'T Nishimura',
'year': '2008',
'unstructured': 'Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth '
'factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 '
'receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. '
'2008;3(7): e2558. https://doi.org/10.1371/journal.pone.0002558.',
'journal-title': 'PLoS ONE'},
{ 'key': '36_CR41',
'doi-asserted-by': 'publisher',
'first-page': '167',
'DOI': '10.1016/j.ejphar.2014.01.064',
'volume': '727',
'author': 'T Ishima',
'year': '2014',
'unstructured': 'Ishima T, Fujita Y, Hashimoto K. Interactions of new antidepressants '
'with sigma-1 receptor chaperons and their potentiation of neurite '
'outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167–73. '
'https://doi.org/10.1016/j.ejphar.2014.01.064.',
'journal-title': 'Eur J Pharmacol'},
{ 'issue': '3',
'key': '36_CR42',
'doi-asserted-by': 'publisher',
'first-page': '193',
'DOI': '10.1002/hup.1106',
'volume': '25',
'author': 'I Hindmarch',
'year': '2010',
'unstructured': 'Hindmarch I, Hashimoto K. Cognition and depression: the effects of '
'fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum '
'Psychopharmacol. 2010;25(3):193–200. https://doi.org/10.1002/hup.1106.',
'journal-title': 'Hum Psychopharmacol'},
{ 'key': '36_CR43',
'doi-asserted-by': 'publisher',
'first-page': '15',
'DOI': '10.1016/j.pneurobio.2012.09.001',
'volume': '100',
'author': 'K Hashimoto',
'year': '2013',
'unstructured': 'Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic '
'factor: emerging links between cardiovascular disease and depression. '
'Prog Neurobiol. 2013;100:15–29. '
'https://doi.org/10.1016/j.pneurobio.2012.09.001.',
'journal-title': 'Prog Neurobiol'},
{ 'issue': '1',
'key': '36_CR44',
'doi-asserted-by': 'publisher',
'first-page': '6',
'DOI': '10.1016/j.jphs.2014.11.010',
'volume': '127',
'author': 'K Hashimoto',
'year': '2015',
'unstructured': 'Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment '
'of neuropsychiatric diseases and its clinical implication. J Pharmacol '
'Sci. 2015;127(1):6–9. https://doi.org/10.1016/j.jphs.2014.11.010.',
'journal-title': 'J Pharmacol Sci'},
{ 'key': '36_CR45',
'doi-asserted-by': 'publisher',
'first-page': '153',
'DOI': '10.1007/978-3-319-50174-1_11',
'volume': '964',
'author': 'Y Albayrak',
'year': '2017',
'unstructured': 'Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical '
'implication in neuropsychiatric disorders. Adv Exp Med Biol. '
'2017;964:153–61. https://doi.org/10.1007/978-3-319-50174-1_11.',
'journal-title': 'Adv Exp Med Biol'},
{ 'issue': '478',
'key': '36_CR46',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/scitranslmed.aau5266',
'volume': '11',
'author': 'DA Rosen',
'year': '2019',
'unstructured': 'Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk '
'JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial '
'in preclinical models of inflammation and sepsis. Sci Transl Med. '
'2019;11(478): eaau5266. https://doi.org/10.1126/scitranslmed.aau5266.',
'journal-title': 'Sci Transl Med'},
{ 'issue': '11',
'key': '36_CR47',
'doi-asserted-by': 'publisher',
'first-page': '6377',
'DOI': '10.1128/JVI.03557-12',
'volume': '87',
'author': 'M Friesland',
'year': '2013',
'unstructured': 'Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 '
'receptor regulates early steps of viral RNA replication at the inset of '
'hepatitis C virus infection. J Virol. 2013;87(11):6377–90. '
'https://doi.org/10.1128/JVI.03557-12.',
'journal-title': 'J Virol'},
{ 'key': '36_CR48',
'doi-asserted-by': 'publisher',
'first-page': '100',
'DOI': '10.1016/j.virusres.2015.03.013',
'volume': '209',
'author': 'C Vasallo',
'year': '2015',
'unstructured': 'Vasallo C, Gastaminza P. Cellular stress response in hepatitis C virus '
'infection: mastering a two-edged sword. Virus Res. 2015;209:100–17. '
'https://doi.org/10.1016/j.virusres.2015.03.013.',
'journal-title': 'Virus Res'},
{ 'key': '36_CR49',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fphar.2020.582310',
'volume': '11',
'author': 'JM Vela',
'year': '2020',
'unstructured': 'Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? '
'Front Pharmacol. 2020;11: 582310. '
'https://doi.org/10.3389/fphar.2020.582310.',
'journal-title': 'Front Pharmacol'},
{ 'issue': '7816',
'key': '36_CR50',
'doi-asserted-by': 'publisher',
'first-page': '459',
'DOI': '10.1038/s41586-020-2286-9',
'volume': '583',
'author': 'DE Gordon',
'year': '2020',
'unstructured': 'Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A '
'SARS-CoV-2 protein interaction map reveals targets for drug repurposing. '
'Nature. 2020;583(7816):459–68. '
'https://doi.org/10.1038/s41586-020-2286-9.',
'journal-title': 'Nature'},
{ 'issue': '6521',
'key': '36_CR51',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/science.abe9403',
'volume': '370',
'author': 'DE Gordon',
'year': '2020',
'unstructured': 'Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. '
'Comparative host-coronavirus protein interaction networks reveal '
'pan-viral disease mechanisms. Science. 2020;370(6521): eabe9403. '
'https://doi.org/10.1126/science.abe9403.',
'journal-title': 'Science'},
{ 'key': '36_CR52',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fphar.2021.652688',
'volume': '12',
'author': 'VP Sukhatme',
'year': '2021',
'unstructured': 'Sukhatme VP, Reiersen AM, Vayttaden SJ, Sykhatme W. Fluvoxamine: a '
'review of its mechanisms of actions and its role in COVID-19. Front '
'Pharmacol. 2021;12: 652688. https://doi.org/10.3389/fphar.2021.652688.',
'journal-title': 'Front Pharmacol'},
{ 'issue': '6',
'key': '36_CR53',
'doi-asserted-by': 'publisher',
'first-page': '435',
'DOI': '10.1080/14728222.2021.1952987',
'volume': '25',
'author': 'JM Brimson',
'year': '2021',
'unstructured': 'Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, '
'Tencomnao T. Drugs that offer the potential to reduce hospitalization '
'and mortality from SARS-CoV-2 infection: the possible role of the '
'sigma-1 receptor and autophagy. Expert Opin Ther Targets. '
'2021;25(6):435–49. https://doi.org/10.1080/14728222.2021.1952987.',
'journal-title': 'Expert Opin Ther Targets'},
{ 'issue': '2',
'key': '36_CR54',
'doi-asserted-by': 'publisher',
'first-page': '280',
'DOI': '10.33594/000000021',
'volume': '52',
'author': 'C Li',
'year': '2019',
'unstructured': 'Li C, Wang A, Wu Y, Gulbins E, Grassmé H, Zhao Z. Acid '
'sphingomyelinase-ceramide system in bacterial infections. Cell Physiol '
'Biochem. 2019;52(2):280–301. https://doi.org/10.33594/000000021.',
'journal-title': 'Cell Physiol Biochem'},
{ 'issue': '11',
'key': '36_CR55',
'doi-asserted-by': 'publisher',
'first-page': '5676',
'DOI': '10.3390/ijms22115676',
'volume': '22',
'author': 'N Beckmann',
'year': '2021',
'unstructured': 'Beckmann N, Becker KA. Ceramide and related molecules in viral '
'infections. Int J Mol Sci. 2021;22(11):5676. '
'https://doi.org/10.3390/ijms22115676.',
'journal-title': 'Int J Mol Sci'},
{ 'key': '36_CR56',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fcell.2021.689854',
'volume': '9',
'author': 'K Törnquist',
'year': '2021',
'unstructured': 'Törnquist K, Asghar MY, Srinivasan V, Korhonen L, Lindholm D. '
'Sphingolipids as modulators of SARS-CoV-2 infection. Front Cell Dev '
'Biol. 2021;9: 689854. https://doi.org/10.3389/fcell.2021.689854.',
'journal-title': 'Front Cell Dev Biol'},
{ 'issue': '1',
'key': '36_CR57',
'doi-asserted-by': 'publisher',
'first-page': '9',
'DOI': '10.1159/000315101',
'volume': '26',
'author': 'J Kornhuber',
'year': '2010',
'unstructured': 'Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, et '
'al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel '
'pharmacological group of drugs with broad clinical applications. Cell '
'Physiol Biochem. 2010;26(1):9–20. https://doi.org/10.1159/000315101.',
'journal-title': 'Cell Physiol Biochem'},
{ 'issue': '1',
'key': '36_CR58',
'doi-asserted-by': 'publisher',
'first-page': '307',
'DOI': '10.1038/s41380-021-01309-5',
'volume': '27',
'author': 'J Kornhuber',
'year': '2022',
'unstructured': 'Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide '
'system in COVID-19. Mol Psychiatry. 2022;27(1):307–14. '
'https://doi.org/10.1038/s41380-021-01309-5.',
'journal-title': 'Mol Psychiatry'},
{ 'issue': '8',
'key': '36_CR59',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pone.0023852',
'volume': '6',
'author': 'J Kornhuber',
'year': '2011',
'unstructured': 'Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et '
'al. Identification of novel functional inhibitors of acid '
'sphingomyelinase. PLoS ONE. 2011;6(8): e23852. '
'https://doi.org/10.1371/journal.pone.0023852.',
'journal-title': 'PLoS ONE'},
{ 'issue': '7',
'key': '36_CR60',
'doi-asserted-by': 'publisher',
'first-page': '934',
'DOI': '10.1038/nm.3214',
'volume': '19',
'author': 'E Gulbins',
'year': '2013',
'unstructured': 'Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, et al. Acid '
'sphingomyelinase-ceramide system mediates effects of antidepressant '
'drugs. Nat Med. 2013;19(7):934–8. https://doi.org/10.1038/nm.3214.',
'journal-title': 'Nat Med'},
{ 'issue': '12',
'key': '36_CR61',
'doi-asserted-by': 'publisher',
'first-page': '2324',
'DOI': '10.1038/s41380-018-0090-9',
'volume': '23',
'author': 'A Gulbins',
'year': '2018',
'unstructured': 'Gulbins A, Schumacher F, Becker KA, Wilker B, Soddemann M, Boldrin F, et '
'al. Antidepressants act by inducing autophagy controlled by '
'sphingomyelin-ceramide. Mol Psychiatry. 2018;23(12):2324–46. '
'https://doi.org/10.1038/s41380-018-0090-9.',
'journal-title': 'Mol Psychiatry'},
{ 'issue': '6',
'key': '36_CR62',
'doi-asserted-by': 'publisher',
'first-page': '1498',
'DOI': '10.1002/cpt.2317',
'volume': '110',
'author': 'N Hoertel',
'year': '2021',
'unstructured': 'Hoertel N, Sánchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze '
'EJ, et al. Association between FIASMAs and reduced risk of intubation or '
'death in individuals hospitalized for severe COVID-19: an observational '
'multicenter study. Clin Pharmacol Ther. 2021;110(6):1498–511. '
'https://doi.org/10.1002/cpt.2317.',
'journal-title': 'Clin Pharmacol Ther'},
{ 'issue': '8',
'key': '36_CR63',
'doi-asserted-by': 'publisher',
'first-page': '878',
'DOI': '10.1016/j.biopsych.2007.04.001',
'volume': '62',
'author': 'M Ishikawa',
'year': '2007',
'unstructured': 'Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. '
'High occupancy of sigma-1 receptors in the human brain after single oral '
'administration of fluvoxamine: a positron emission tomography study '
'using [11C]SA4503. Biol Psychiatry. 2007;62(8):878–83. '
'https://doi.org/10.1016/j.biopsych.2007.04.001.',
'journal-title': 'Biol Psychiatry'},
{ 'key': '36_CR64',
'unstructured': 'Lenze E. Fluvoxamine for early treatment of Covid-19 (Stop Covid 2). '
'ClinicalTrials.gov Identifier: NCT04668950.'},
{ 'issue': '2',
'key': '36_CR65',
'doi-asserted-by': 'publisher',
'DOI': '10.1093/ofid/ofab050',
'volume': '8',
'author': 'D Seftel',
'year': '2021',
'unstructured': 'Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early '
'treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2): '
'ofab050. https://doi.org/10.1093/ofid/ofab050.',
'journal-title': 'Open Forum Infect Dis'},
{ 'issue': '1',
'key': '36_CR66',
'doi-asserted-by': 'publisher',
'first-page': 'e42',
'DOI': '10.1016/S2214-109X(21)00448-4',
'volume': '10',
'author': 'G Reis',
'year': '2022',
'unstructured': 'Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Milagres AC, '
'Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk '
'of emergency care and hospitalization among patients with COVID-19: the '
'TOGETHER randomized, platform clinical trial. Lancet Glob Health. '
'2022;10(1):e42–51. https://doi.org/10.1016/S2214-109X(21)00448-4.',
'journal-title': 'Lancet Glob Health'},
{ 'issue': '5',
'key': '36_CR67',
'doi-asserted-by': 'publisher',
'first-page': '2065',
'DOI': '10.1111/bcp.15126',
'volume': '88',
'author': 'M Calusic',
'year': '2022',
'unstructured': 'Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. '
'Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open '
'label, prospective cohort trial with matched controls. Bri J Clin '
'Pharmacol. 2022;88(5):2065–73. https://doi.org/10.1111/bcp.15126.',
'journal-title': 'Bri J Clin Pharmacol'},
{ 'issue': '11',
'key': '36_CR68',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2021.33090',
'volume': '4',
'author': 'T Oskotsky',
'year': '2021',
'unstructured': 'Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. '
'Mortality risk among patients with COVID-19 prescribed selective '
'serotonin reuptake inhibitor antidepressants. JAMA Netw Open. '
'2021;4(11): e2133090. '
'https://doi.org/10.1001/jamanetworkopen.2021.33090.',
'journal-title': 'JAMA Netw Open'},
{ 'key': '36_CR69',
'doi-asserted-by': 'publisher',
'first-page': '1054644',
'DOI': '10.3389/fphar.2022.1054644',
'volume': '13',
'author': 'E Pineda',
'year': '2022',
'unstructured': 'Pineda E, Singh J, Pineda MV, Umanzor JG, Baires F, Benitez LG, et al. '
'Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in '
'a prospective observational real-world study. Front Pharmacol. '
'2022;13:1054644. https://doi.org/10.3389/fphar.2022.1054644.',
'journal-title': 'Front Pharmacol'},
{ 'issue': '1',
'key': '36_CR70',
'doi-asserted-by': 'publisher',
'first-page': '102',
'DOI': '10.3947/ic.2021.0142',
'volume': '54',
'author': 'H Seo',
'year': '2022',
'unstructured': 'Seo H, Kim H, Bae S, Park S, Chung H, Sung HS, et al. Fluvoxamine '
'treatment of patients with symptomatic COVID-19 in a community treatment '
'center: a preliminary result of randomized controlled trial. Infect '
'Chemother. 2022;54(1):102–13. https://doi.org/10.3947/ic.2021.0142.',
'journal-title': 'Infect Chemother'},
{ 'issue': '7',
'key': '36_CR71',
'doi-asserted-by': 'publisher',
'first-page': '599',
'DOI': '10.1056/NEJMoa2201662',
'volume': '387',
'author': 'CT Bramante',
'year': '2022',
'unstructured': 'Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas '
'JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine '
'for Covid-19. N Engl J Med. 2022;387(7):599–610. '
'https://doi.org/10.1056/NEJMoa2201662.',
'journal-title': 'N Engl J Med'},
{ 'issue': '4',
'key': '36_CR72',
'doi-asserted-by': 'publisher',
'first-page': '296',
'DOI': '10.1001/jama.2022.24100',
'volume': '329',
'author': 'MW McCarthy',
'year': '2023',
'unstructured': 'McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, '
'et al. Effect of fluvoxamine vs placebo on time to sustained recovery in '
'outpatients with mild to moderate COVID-19: a randomized clinical trial. '
'JAMA. 2023;329(4):296–305. https://doi.org/10.1001/jama.2022.24100.',
'journal-title': 'JAMA'},
{ 'issue': '4',
'key': '36_CR73',
'doi-asserted-by': 'publisher',
'first-page': '291',
'DOI': '10.1001/jama.2022.23954',
'volume': '329',
'author': 'A Bhimraj',
'year': '2023',
'unstructured': 'Bhimraj A, Gallagher JC. Lack of benefit of fluvoxamine for COVID-19. '
'JAMA. 2023;329(4):291–2. https://doi.org/10.1001/jama.2022.23954.',
'journal-title': 'JAMA'},
{ 'issue': '5',
'key': '36_CR74',
'doi-asserted-by': 'publisher',
'first-page': '22br03337',
'DOI': '10.4088/PCC.22br03337',
'volume': '24',
'author': 'AD Diaz',
'year': '2022',
'unstructured': 'Diaz AD, Baweja R. Protective effect of fluvoxamine for COVID-19 in '
'obsessive–compulsive disorder: a real-world case-control study. Prim '
'Care Comp CNS Disord. 2022;24(5):22br03337. '
'https://doi.org/10.4088/PCC.22br03337.',
'journal-title': 'Prim Care Comp CNS Disord'},
{ 'issue': '6',
'key': '36_CR75',
'doi-asserted-by': 'publisher',
'first-page': '590',
'DOI': '10.1056/NEJMc2011400',
'volume': '383',
'author': 'VG Puelles',
'year': '2020',
'unstructured': 'Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, '
'Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J '
'Med. 2020;383(6):590–2. https://doi.org/10.1056/NEJMc2011400.',
'journal-title': 'N Engl J Med'},
{ 'issue': '10',
'key': '36_CR76',
'doi-asserted-by': 'publisher',
'first-page': '989',
'DOI': '10.1056/NEJMc2019373',
'volume': '383',
'author': 'IH Solomon',
'year': '2020',
'unstructured': 'Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, '
'et al. Neurological features of Covid-19. N Engl J Med. '
'2020;383(10):989–92. https://doi.org/10.1056/NEJMc2019373.',
'journal-title': 'N Engl J Med'},
{ 'issue': '3',
'key': '36_CR77',
'doi-asserted-by': 'publisher',
'first-page': '368',
'DOI': '10.1038/s41593-020-00771-8',
'volume': '24',
'author': 'EM Rhea',
'year': '2021',
'unstructured': 'Rhea EM, Logsdon AF, Hansen KM, Williams LM, Reed MJ, Baumann KK, et al. '
'The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. '
'Nat Neurosci. 2021;24(3):368–78. '
'https://doi.org/10.1038/s41593-020-00771-8.',
'journal-title': 'Nat Neurosci'},
{ 'issue': '1',
'key': '36_CR78',
'doi-asserted-by': 'publisher',
'first-page': '337',
'DOI': '10.1038/s41392-021-00719-9',
'volume': '6',
'author': 'L Zhang',
'year': '2021',
'unstructured': 'Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. SAES-CoV-2 crosses '
'the blood–brain barrier accompanied with basement membrane disruption '
'without tight junctions alteration. Signal Transduct Target. '
'2021;6(1):337. https://doi.org/10.1038/s41392-021-00719-9.',
'journal-title': 'Signal Transduct Target'},
{ 'issue': '1',
'key': '36_CR79',
'doi-asserted-by': 'publisher',
'first-page': '188',
'DOI': '10.3390/biomedicines10010188',
'volume': '10',
'author': 'D Petrovszki',
'year': '2022',
'unstructured': 'Petrovszki D, Walter FR, Vigh JP, Kocsis A, Valkai S, Deli MA, Dér A. '
'Penetration of the SARS-CoV-2 spike protein across the blood-brain '
'barrier, as revealed by a combination of a human cell culture model '
'system and optical biosensing. Biomedicines. 2022;10(1):188. '
'https://doi.org/10.3390/biomedicines10010188.',
'journal-title': 'Biomedicines'},
{ 'issue': '7907',
'key': '36_CR80',
'doi-asserted-by': 'publisher',
'first-page': '697',
'DOI': '10.1038/s41586-022-04569-5',
'volume': '604',
'author': 'G Douaud',
'year': '2022',
'unstructured': 'Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et '
'al. SARS-CoV-2 is associated with changes in brain structure in UK '
'Biobank. Nature. 2022;604(7907):697–707. '
'https://doi.org/10.1038/s41586-022-04569-5.',
'journal-title': 'Nature'},
{ 'issue': '1',
'key': '36_CR81',
'doi-asserted-by': 'publisher',
'first-page': '230',
'DOI': '10.1038/s41392-022-01072-1',
'volume': '7',
'author': 'N Sollmann',
'year': '2022',
'unstructured': 'Sollmann N, Beer AJ, Kirchhoff F. SARS-CoV-2 infection and the brain: '
'direct evidence for brain changes in milder cases. Signal Transduct '
'Target Ther. 2022;7(1):230. https://doi.org/10.1038/s41392-022-01072-1.',
'journal-title': 'Signal Transduct Target Ther'},
{ 'issue': '3',
'key': '36_CR82',
'doi-asserted-by': 'publisher',
'DOI': '10.1084/jem.20202135',
'volume': '218',
'author': 'E Song',
'year': '2021',
'unstructured': 'Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et '
'al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. '
'2021;218(3): e20202135. https://doi.org/10.1084/jem.20202135.',
'journal-title': 'J Exp Med'},
{ 'issue': '7941',
'key': '36_CR83',
'doi-asserted-by': 'publisher',
'first-page': '758',
'DOI': '10.1038/s41586-022-05542-y',
'volume': '612',
'author': 'SR Stein',
'year': '2022',
'unstructured': 'Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. '
'SARS-CoV-2 infection and persistence in the human body and brain at '
'autopsy. Nature. 2022;612(7941):758–63. '
'https://doi.org/10.1038/s41586-022-05542-y.',
'journal-title': 'Nature'},
{ 'key': '36_CR84',
'doi-asserted-by': 'publisher',
'first-page': '18',
'DOI': '10.1016/j.bbi.2020.03.031',
'volume': '87',
'author': 'Y Wu',
'year': '2020',
'unstructured': 'Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system '
'involvement after infection with COVID-19 and other coronaviruses. Brain '
'Behav Immun. 2020;87:18–22. https://doi.org/10.1016/j.bbi.2020.03.031.',
'journal-title': 'Brain Behav Immun'},
{ 'issue': '5',
'key': '36_CR85',
'doi-asserted-by': 'publisher',
'first-page': '2681',
'DOI': '10.3390/ijms22052681',
'volume': '22',
'author': 'MA Erickson',
'year': '2021',
'unstructured': 'Erickson MA, Rhea EM, Knopp RC, Banks WA. Interactions of SARS-CoV-2 '
'with the blood–brain barrier. Int J Mol Sci. 2021;22(5):2681. '
'https://doi.org/10.3390/ijms22052681.',
'journal-title': 'Int J Mol Sci'},
{ 'issue': '1',
'key': '36_CR86',
'doi-asserted-by': 'publisher',
'first-page': '1',
'DOI': '10.3390/vaccines10010001',
'volume': '10',
'author': 'PR Oldfield',
'year': '2021',
'unstructured': 'Oldfield PR, Hibberd J, Bridle BW. How does severe acute respiratory '
'syndrome-coronavirus-2 affect the brain and its implications for the '
'vaccines currently in use. Vaccines (Basel). 2021;10(1):1. '
'https://doi.org/10.3390/vaccines10010001.',
'journal-title': 'Vaccines (Basel)'},
{ 'issue': '6',
'key': '36_CR87',
'doi-asserted-by': 'publisher',
'first-page': '682',
'DOI': '10.1001/jamapsychiatry.2021.0500',
'volume': '78',
'author': 'M Boldrini',
'year': '2021',
'unstructured': 'Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA '
'Psychiat. 2021;78(6):682–3. '
'https://doi.org/10.1001/jamapsychiatry.2021.0500.',
'journal-title': 'JAMA Psychiat'},
{ 'issue': '3',
'key': '36_CR88',
'doi-asserted-by': 'publisher',
'first-page': '1850',
'DOI': '10.1007/s12035-021-02696-0',
'volume': '59',
'author': 'TC Theoharides',
'year': '2022',
'unstructured': 'Theoharides TC. Could SARS-CoV-2 spike protein be responsible for '
'long-COVID syndrome? Mol Neurobiol. 2022;59(3):1850–61. '
'https://doi.org/10.1007/s12035-021-02696-0.',
'journal-title': 'Mol Neurobiol'},
{ 'issue': '10',
'key': '36_CR89',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2021.28568',
'volume': '4',
'author': 'D Groff',
'year': '2021',
'unstructured': 'Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. '
'Short-term and long-term rates of postacute sequelae of SARS-CoV-2 '
'infection: a systematic review. JAMA Netw Open. 2021;4(10): e2128568. '
'https://doi.org/10.1001/jamanetworkopen.2021.28568.',
'journal-title': 'JAMA Netw Open'},
{ 'key': '36_CR90',
'doi-asserted-by': 'publisher',
'author': 'HE Davis',
'year': '2023',
'unstructured': 'Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, '
'mechanisms and recommendation. Nat Rev Microbiol. 2023. '
'https://doi.org/10.1038/s41579-022-00846-2.',
'journal-title': 'Nat Rev Microbiol',
'DOI': '10.1038/s41579-022-00846-2'},
{ 'issue': '12',
'key': '36_CR91',
'doi-asserted-by': 'publisher',
'first-page': '4768',
'DOI': '10.7150/ijbs.75056',
'volume': '18',
'author': 'HC Koc',
'year': '2022',
'unstructured': 'Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int '
'J Biol Sci. 2022;18(12):4768–80. https://doi.org/10.7150/ijbs.75056.',
'journal-title': 'Int J Biol Sci'},
{ 'key': '36_CR92',
'doi-asserted-by': 'publisher',
'author': 'H Sidky',
'year': '2022',
'unstructured': 'Sidky H, Sahner DK, Girvin AT, Hotaling N, Michael SG, Kurilla MG, et '
'al. Assessing the effect of selective serotonin reuptake inhibitors in '
'the prevention of post-acute sequelae of COVID-19. medRxiv. 2022. '
'https://doi.org/10.1101/2022.11.09.22282142.',
'journal-title': 'medRxiv',
'DOI': '10.1101/2022.11.09.22282142'},
{ 'issue': '2',
'key': '36_CR93',
'doi-asserted-by': 'publisher',
'first-page': '65',
'DOI': '10.1007/s40267-022-00975-x',
'volume': '39',
'author': 'C Fenton',
'year': '2023',
'unstructured': 'Fenton C, Lee A. Antidepressants with anti-inflammatory properties may '
'be useful in long COVID depression. Drugs Ther Perspect. '
'2023;39(2):65–70. https://doi.org/10.1007/s40267-022-00975-x.',
'journal-title': 'Drugs Ther Perspect'},
{ 'issue': '9',
'key': '36_CR94',
'doi-asserted-by': 'publisher',
'first-page': '3562',
'DOI': '10.1038/s41380-022-01545-3',
'volume': '27',
'author': 'E Khani',
'year': '2022',
'unstructured': 'Khani E, Entezari-Maleki T. Fluvoxamine and long COVID-19: a new role '
'for sigma-1 receptor (S1R) agonists. Mol Psychiatry. 2022;27(9):3562. '
'https://doi.org/10.1038/s41380-022-01545-3.',
'journal-title': 'Mol Psychiatry'},
{ 'issue': '9',
'key': '36_CR95',
'doi-asserted-by': 'publisher',
'first-page': '3563',
'DOI': '10.1038/s41380-022-01546-2',
'volume': '27',
'author': 'Y Hashimoto',
'year': '2022',
'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Comments to “Fluvoxamine and long '
'COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and '
'Entezari-Maleki. Mol Psychiatry. 2022;27(9):3563–4. '
'https://doi.org/10.1038/s41380-022-01546-2.',
'journal-title': 'Mol Psychiatry'},
{ 'issue': '5',
'key': '36_CR96',
'doi-asserted-by': 'publisher',
'first-page': '1315',
'DOI': '10.4269/ajtmh.21-1310',
'volume': '106',
'author': 'CM Guo',
'year': '2022',
'unstructured': 'Guo CM, Harari O, Chernecki C, Thorlund K, Forrest JI. Fluvoxamine for '
'the early treatment of COVID-19: a meta-analysis of randomized clinical '
'trials. Am J Trop Med Hyg. 2022;106(5):1315–20. '
'https://doi.org/10.4269/ajtmh.21-1310.',
'journal-title': 'Am J Trop Med Hyg'},
{ 'issue': '3',
'key': '36_CR97',
'doi-asserted-by': 'publisher',
'first-page': 'e298',
'DOI': '10.1097/MJT.0000000000001496',
'volume': '29',
'author': 'S Bhuta',
'year': '2022',
'unstructured': 'Bhuta S, Khokher W, Kesireddy N, Iftikhar S, Beran A, Mhanna M, et al. '
'Fluvoxamine in nonhospitalized patients with acute COVID-19 infection '
'and the lack of efficacy in reducing rates of hospitalization, '
'mechanical ventilation, and mortality in placebo-controlled trials: a '
'systematic review and meta-analysis. Am J Ther. 2022;29(3):e298–304. '
'https://doi.org/10.1097/MJT.0000000000001496.',
'journal-title': 'Am J Ther'},
{ 'issue': '4',
'key': '36_CR98',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jamanetworkopen.2022.6269',
'volume': '5',
'author': 'TC Lee',
'year': '2022',
'unstructured': 'Lee TC, Vigod S, Bortolussi-Courval É, Hanula R, Boulware DR, Lenze EJ, '
'et al. Fluvoxamine for outpatients management of COVID-19 to prevent '
'hospitalization: a systematic review and meta-analysis. JAMA Netw Open. '
'2022;5(4): e226269. https://doi.org/10.1001/jamanetworkopen.2022.6269.',
'journal-title': 'JAMA Netw Open'},
{ 'issue': '6',
'key': '36_CR99',
'doi-asserted-by': 'publisher',
'first-page': '702',
'DOI': '10.1016/j.jinf.2022.10.012',
'volume': '85',
'author': 'HA Cheema',
'year': '2022',
'unstructured': 'Cheema HA, Jafar U, Elrashedy AA, Shahid A, Awan RU, Ehsan M, et al. '
'Efficacy and safety of fluvoxamine for the treatment of COVID-19 '
'patients. J Infect. 2022;85(6):702–69. '
'https://doi.org/10.1016/j.jinf.2022.10.012.',
'journal-title': 'J Infect'},
{ 'issue': '11',
'key': '36_CR100',
'doi-asserted-by': 'publisher',
'first-page': '1259',
'DOI': '10.1016/j.jiph.2022.10.010',
'volume': '15',
'author': 'LC Lu',
'year': '2022',
'unstructured': 'Lu LC, Chao CM, Chang SP, Lan SH, Lai CC. Effect of fluvoxamine on '
'outcomes of nonhospitalized patients with COVID-19: a systematic review '
'and meta-analysis. J Infect Public Health. 2022;15(11):1259–64. '
'https://doi.org/10.1016/j.jiph.2022.10.010.',
'journal-title': 'J Infect Public Health'},
{ 'issue': '2',
'key': '36_CR101',
'doi-asserted-by': 'publisher',
'first-page': '154',
'DOI': '10.1016/j.jinf.2022.11.011',
'volume': '86',
'author': 'R Marcec',
'year': '2023',
'unstructured': 'Marcec R, Dodig VM, Likic R. A meta-analysis regarding fluvoxamine and '
'hospitalization risk of COVID-19 patients: TOGETHER making a difference. '
'J Infect. 2023;86(2):154–225. '
'https://doi.org/10.1016/j.jinf.2022.11.011.',
'journal-title': 'J Infect'},
{ 'issue': '2',
'key': '36_CR102',
'doi-asserted-by': 'publisher',
'first-page': '154',
'DOI': '10.1016/j.jinf.2022.11.016',
'volume': '86',
'author': 'V Trkulja',
'year': '2023',
'unstructured': 'Trkulja V. There is no reasonable evidence to support efficacy of '
'fluvoxamine in prevention of disease deterioration in COVID-19 '
'outpatients: a comment on two recent meta-analyses advocating its use. J '
'Infect. 2023;86(2):154–225. https://doi.org/10.1016/j.jinf.2022.11.016.',
'journal-title': 'J Infect'},
{ 'issue': '2',
'key': '36_CR103',
'doi-asserted-by': 'publisher',
'first-page': '321',
'DOI': '10.1007/s00228-022-03447-3',
'volume': '79',
'author': 'V Trkulja',
'year': '2023',
'unstructured': 'Trkulja V. Why we should not recommend or offer fluvoxamine to COVID-19 '
'patients? Eur J Clin Pharmacol. 2023;79(2):321–2. '
'https://doi.org/10.1007/s00228-022-03447-3.',
'journal-title': 'Eur J Clin Pharmacol'},
{ 'key': '36_CR104',
'doi-asserted-by': 'publisher',
'author': 'J Deng',
'year': '2023',
'unstructured': 'Deng J, Rayner D, Ba Ramaraju H, Abbas U, Carcia C, Heybati K, et al. '
'Efficacy and safety of selective serotonin reuptake inhibitors in '
'COVID-19 management: a systematic review and meta-analysis. Clin '
'Microbiol Infect. 2023. https://doi.org/10.1016/j.cmi.2023.01.010.',
'journal-title': 'Clin Microbiol Infect',
'DOI': '10.1016/j.cmi.2023.01.010'},
{ 'key': '36_CR105',
'doi-asserted-by': 'publisher',
'unstructured': 'Kirenga BJ, Mugenyi L, Sánchez-Rico M, Kyobe H, Muttamba W, Mugume R, et '
'al. Association of fluvoxamine with mortality and symptom resolution '
'among inpatients with COVID-19 in Uganda: a prospective interventional '
'open-label cohort study. Mol Psychiatry. 2023;1–8. '
'https://doi.org/10.1038/s41380-023-02004-3.',
'DOI': '10.1038/s41380-023-02004-3'},
{ 'issue': '7',
'key': '36_CR106',
'doi-asserted-by': 'publisher',
'first-page': '3812',
'DOI': '10.3390/ijms23073812',
'volume': '23',
'author': 'M Mahdi',
'year': '2022',
'unstructured': 'Mahdi M, Hermán L, Réthelyi JM, Bálint BL. Potential role of the '
'antidepressants fluoxetine and fluvoxamine in the treatment of COVID-19. '
'Int J Mol Sci. 2022;23(7):3812. https://doi.org/10.3390/ijms23073812.',
'journal-title': 'Int J Mol Sci'},
{ 'issue': '1',
'key': '36_CR107',
'doi-asserted-by': 'publisher',
'first-page': '101',
'DOI': '10.4269/ajtmh.22-0106',
'volume': '108',
'author': 'FP Mills',
'year': '2022',
'unstructured': 'Mills FP, Reis G, Wilson LA, Thorlund K, Forrest JI, Guo CM, et al. '
'Early treatment with fluvoxamine among patients with COVID-19: a '
'cost-consequence model. Am J Trop Med Hyg. 2022;108(1):101–6. '
'https://doi.org/10.4269/ajtmh.22-0106.',
'journal-title': 'Am J Trop Med Hyg'}],
'container-title': 'Discover Mental Health',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s44192-023-00036-3.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://link.springer.com/article/10.1007/s44192-023-00036-3/fulltext.html',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://link.springer.com/content/pdf/10.1007/s44192-023-00036-3.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 3, 21]],
'date-time': '2023-03-21T14:09:07Z',
'timestamp': 1679407747000},
'score': 1,
'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s44192-023-00036-3'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 3, 21]]},
'references-count': 107,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 12]]}},
'alternative-id': ['36'],
'URL': 'http://dx.doi.org/10.1007/s44192-023-00036-3',
'relation': {},
'ISSN': ['2731-4383'],
'container-title-short': 'Discov Ment Health',
'published': {'date-parts': [[2023, 3, 21]]},
'assertion': [ { 'value': '25 January 2023',
'order': 1,
'name': 'received',
'label': 'Received',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '2 March 2023',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '21 March 2023',
'order': 3,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}},
{ 'value': 'Dr. Hashimoto is the inventor of filed patent applications on “The use of '
'<i>R</i>-Ketamine in the treatment of psychiatric diseases”, '
'“(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine '
'and derivative thereof as prophylactic or therapeutic agent for '
'neurodegeneration disease or recognition function disorder”, “Preventive or '
'therapeutic agent and pharmaceutical composition for inflammatory diseases or '
'bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or '
'therapeutic agent for a neurodevelopmental disorder” by the Chiba University. '
'Dr. Hashimoto has also received speakers’ honoraria, consultant fee, or '
'research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika '
'Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami '
'Farm and Perception Neuroscience.',
'order': 2,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}],
'article-number': '9'}
